JP6602840B2 - 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 - Google Patents

可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 Download PDF

Info

Publication number
JP6602840B2
JP6602840B2 JP2017503554A JP2017503554A JP6602840B2 JP 6602840 B2 JP6602840 B2 JP 6602840B2 JP 2017503554 A JP2017503554 A JP 2017503554A JP 2017503554 A JP2017503554 A JP 2017503554A JP 6602840 B2 JP6602840 B2 JP 6602840B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
reduced pressure
under reduced
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017503554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521457A5 (OSRAM
JP2017521457A (ja
Inventor
ジェロッド バーネット ブレネマン
ジョン デイヴィッド ジン
クリストファー ロナルド サルコ
ジョン ウェストブルック
チョンフア チャン
マオリン ユー
タマラ デニス ホプキンス
マイケル ディー ロウ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6602840(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017521457A publication Critical patent/JP2017521457A/ja
Publication of JP2017521457A5 publication Critical patent/JP2017521457A5/ja
Application granted granted Critical
Publication of JP6602840B2 publication Critical patent/JP6602840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
JP2017503554A 2014-07-22 2015-07-21 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 Active JP6602840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462027376P 2014-07-22 2014-07-22
US62/027,376 2014-07-22
PCT/US2015/041245 WO2016014463A1 (en) 2014-07-22 2015-07-21 Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Publications (3)

Publication Number Publication Date
JP2017521457A JP2017521457A (ja) 2017-08-03
JP2017521457A5 JP2017521457A5 (OSRAM) 2018-08-30
JP6602840B2 true JP6602840B2 (ja) 2019-11-06

Family

ID=53783363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017503554A Active JP6602840B2 (ja) 2014-07-22 2015-07-21 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸

Country Status (26)

Country Link
US (1) US9353090B2 (OSRAM)
EP (1) EP3172202B1 (OSRAM)
JP (1) JP6602840B2 (OSRAM)
KR (1) KR20170035993A (OSRAM)
CN (1) CN106459017B (OSRAM)
AP (1) AP2016009615A0 (OSRAM)
AR (1) AR101265A1 (OSRAM)
AU (1) AU2015292833B2 (OSRAM)
BR (1) BR112017000943A2 (OSRAM)
CA (1) CA2955937A1 (OSRAM)
CL (1) CL2017000071A1 (OSRAM)
CO (1) CO2017000438A2 (OSRAM)
DK (1) DK3172202T3 (OSRAM)
EA (1) EA032972B1 (OSRAM)
ES (1) ES2784477T3 (OSRAM)
HU (1) HUE049231T2 (OSRAM)
IL (1) IL249587A0 (OSRAM)
MX (1) MX378717B (OSRAM)
PE (1) PE20170249A1 (OSRAM)
PH (1) PH12017500111A1 (OSRAM)
PL (1) PL3172202T3 (OSRAM)
PT (1) PT3172202T (OSRAM)
SG (2) SG11201700507XA (OSRAM)
TW (1) TWI711615B (OSRAM)
UY (1) UY36226A (OSRAM)
WO (1) WO2016014463A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012001A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
KR102456406B1 (ko) 2016-09-14 2022-10-19 게노마티카 인코포레이티드 1,3-지방 디올 화합물 및 그 유도체
EP3525778A1 (de) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
CN106495999B (zh) * 2016-10-18 2019-08-16 亳州学院 一种芳香醛及其合成方法
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
CA3069554A1 (en) 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibitors of leucine rich repeat kinase 2
WO2019036000A1 (en) * 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
WO2019207517A1 (en) * 2018-04-27 2019-10-31 Hetero Labs Limited Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d 3)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
JP7314173B2 (ja) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
US12234217B2 (en) 2018-12-03 2025-02-25 Fmc Corporation Method for preparing N-phenylpyrazole-1-carboxamides
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
MX2023000614A (es) 2020-07-16 2023-02-13 Acuitas Therapeutics Inc Lipidos cationicos para usarse en nanoparticulas lipidicas.
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
EP1906957A1 (en) 2005-07-18 2008-04-09 Bayer HealthCare AG Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
EP2144605A1 (en) 2007-05-12 2010-01-20 Bayer HealthCare AG sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2207541B1 (en) 2007-10-05 2014-10-29 Sanofi-Aventis Deutschland GmbH Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA32967B1 (fr) 2009-01-17 2012-01-02 Bayer Schering Pharma Ag Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
RS54336B1 (sr) 2010-02-05 2016-02-29 Adverio Pharma Gmbh Sgc stimulatori ili sgc aktivatori, sami za sebe i kombinovani sa pde5 inhibitorima za tretman cistične fibroze
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) * 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
DK2892891T3 (da) 2012-09-07 2019-10-14 Boehringer Ingelheim Int Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma

Also Published As

Publication number Publication date
CN106459017B (zh) 2020-07-17
TW201617340A (zh) 2016-05-16
EA032972B1 (ru) 2019-08-30
PE20170249A1 (es) 2017-04-05
AU2015292833A1 (en) 2016-12-22
PL3172202T3 (pl) 2020-07-13
PT3172202T (pt) 2020-05-06
AP2016009615A0 (en) 2016-12-31
US9353090B2 (en) 2016-05-31
TWI711615B (zh) 2020-12-01
SG11201700507XA (en) 2017-02-27
UY36226A (es) 2016-01-29
HUE049231T2 (hu) 2020-09-28
AR101265A1 (es) 2016-12-07
US20160024059A1 (en) 2016-01-28
WO2016014463A1 (en) 2016-01-28
AU2015292833B2 (en) 2019-11-28
IL249587A0 (en) 2017-02-28
SG10201806565SA (en) 2018-08-30
EA201790246A1 (ru) 2017-07-31
CL2017000071A1 (es) 2017-06-30
EP3172202B1 (en) 2020-01-29
CA2955937A1 (en) 2016-01-28
ES2784477T3 (es) 2020-09-28
CO2017000438A2 (es) 2017-08-31
KR20170035993A (ko) 2017-03-31
EP3172202A1 (en) 2017-05-31
PH12017500111A1 (en) 2017-05-29
DK3172202T3 (da) 2020-04-27
BR112017000943A2 (pt) 2017-11-14
JP2017521457A (ja) 2017-08-03
CN106459017A (zh) 2017-02-22
MX378717B (es) 2025-03-10
MX2017000926A (es) 2017-05-04

Similar Documents

Publication Publication Date Title
JP6602840B2 (ja) 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸
JP5970134B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール
EP2683710B1 (en) Soluble guanylate cyclase activators
JP5826393B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子
CN104011052B (zh) 化合物
CN103596952B (zh) 作为Syk抑制剂的新型取代的吡啶并吡嗪类化合物
TW202122391A (zh) Ｒｉｐ１抑制性化合物及用於製備和使用其之方法後補
TWI617551B (zh) 新穎吡啶衍生物
WO2018065962A1 (en) Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
HK1210178A1 (en) Substituted pyridopyrazines as syk inhibitors
JPWO2019189555A1 (ja) 複素環化合物
TW202317560A (zh) Ｃｄｋ２抑制劑及其使用方法
CN115843295A (zh) Nampt调节剂
WO2023098825A1 (zh) Sos1抑制剂、包含其的药物组合物及其用途
CN119053596A (zh) 作为激酶抑制剂的杂环化合物、其组合物及使用方法
HK1210164B (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
CN104812753A (zh) 作为Syk抑制剂的取代吡啶并吡嗪类化合物
HK1190143B (en) Substituted pyridopyrazines as novel syk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180723

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191009

R150 Certificate of patent or registration of utility model

Ref document number: 6602840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250